Page last updated: 2024-11-13
prednisolone sodium succinate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
prednisolone sodium succinate : The organic sodium salt of prednisolone succinate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23680518 |
| CHEMBL ID | 1412530 |
| CHEBI ID | 32044 |
| SCHEMBL ID | 122046 |
| MeSH ID | M0076033 |
Synonyms (64)
| Synonym |
|---|
| 8223rr9dwf , |
| prednisolone sodium succinate [usp:jan] |
| unii-8223rr9dwf |
| sodium 4-{[(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]oxy}-4-oxobutanoate |
| sodium prednisolone 21-hemisuccinate |
| nsc9151 |
| methyprednisolone sodium succinate |
| prednisolone 21-hemisuccinate sodium salt |
| nsc-9151 |
| meticortelane |
| prednisolone 21-succinate sodium salt |
| prednisolone 21-succinate sodium |
| di-adreson f-aquosum |
| prednisolone sodium 21-hemisuccinate |
| prednisolone sodium hemisuccinate |
| solu-decortin |
| prednisolone 21-hemisuccinate sodium |
| meticortelone, soluble |
| prednisolone sodium succinate, injection |
| prednisolone 21-sodium succinate |
| prednisolone sodium succinate |
| 1715-33-9 |
| pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(hydrogen succinate), monosodium salt |
| pregna-1,4-diene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11beta)- |
| 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(sodium succinate) |
| pregna-1,4-diene-3,20-dione, 21-(3-carboxyl-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11beta)- |
| nsc 9151 |
| predonine soluble |
| solu-delta-cortef (veterinary) |
| pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-, 21-(hydrogen succinate), monosodium salt |
| einecs 216-995-1 |
| MLS001424152 |
| smr000058773 |
| MLS000069574 |
| delta1-hydrocortisone 21-hemisuccinate sodium salt |
| HMS2051N20 |
| HMS2231M04 |
| CHEMBL1412530 |
| CCG-101061 |
| prednisolone sodium succinate [mart.] |
| prednisolone 21-succinate sodium salt [mi] |
| pregna-1,4-diene-3,20-dione, 21-(3-carboxyl-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11.beta.)- |
| prednisolone sodium succinate [who-dd] |
| prednisolone sodium succinate for injection [jan] |
| prednisolone sodium succinate [green book] |
| prednisolone sodium succinate [usp impurity] |
| SCHEMBL122046 |
| NC00311 |
| sodium 4-[(11beta,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl)oxy]-4-oxobutanoate |
| CHEBI:32044 , |
| kohakusanin |
| AKOS025286104 |
| DTXSID8023503 , |
| J-010731 |
| BCP28839 |
| Q27269293 |
| sodium;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate |
| solu-delta cortef sterile powder |
| sodium 4-((11beta,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl)oxy)-4-oxobutanoate |
| dtxcid503503 |
| prednisolone sodium succinate (usp impurity) |
| prednisolone sodium succinate (mart.) |
| precortalon aquosum |
| sodium 4-{2-[(1r,3as,3bs,9ar,9bs,10s,11as)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| anti-inflammatory drug | A substance that reduces or suppresses inflammation. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| organic sodium salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 0.6310 | 0.0013 | 7.7625 | 44.6684 | AID914; AID915 |
| IDH1 | Homo sapiens (human) | Potency | 1.1582 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.1386 | 0.0041 | 9.9848 | 25.9290 | AID504444; AID720524 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 19.9526 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.24
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.24) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||